The short version of alpha-MSH analog fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-05 and is reviewed periodically as new material appears.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
gene trapping A high-throughput technology used to simultaneously inactivate, identify, and report the expression of a target gene in a mammalian genome by introducing an insertional mutation consisting of a promoterless reporter gene and/or a selectable marker flanked by an upstream splice site and a downstream polyadenylated termination sequence.
Low complexity regions in proteins can be computationally detected from sequence using various methods and definitions, as reviewed in. Among the most popular methodologies to identify LCRs is by measuring their Shannon entropy. The lower the value of the calculated entropy, the more homogeneous the region is in terms of amino acid content. In addition, a Neural Network webserver, LCR-hound has been developed to predict the function of an LCR, based on its amino acid or di-amino acid (bigram) content. Compression-based tools have also been used to perform such analysis providing higher sensitivity while mitigating the risk of overestimation inherent in other methods.
Car hit and runs, burglaries, assaults, drive-by shootings and bombings such as these situations may cause glass fragments that could be used as evidence of association in glass transfer conditions. LA-ICP-MS is considered one of the best techniques for analysis of glass due to the short time for sample preparation and sample, small sample size of less than 250 nanograms. In addition there is no need for complex procedure and handling of dangerous materials that is used for digestion of the samples. This allows detecting major, minor and tracing elements with high level of precision and accuracy. There are set of properties that are used to measure glass sample such as physical and optical properties including color, thickness, density, refractive index (RI) and also, if necessary, elemental analysis can be conducted in order to enhance the value of an association.
Sources: en.wikipedia.org
The chemical structure of penicillin was first suggested by Abraham in 1942. Dorothy Hodgkin determined the correct chemical structure of penicillin using X-ray crystallography at Oxford in 1945. In 1945, the US Committee on Medical Research and the British Medical Research Council jointly published in Science chemical analyses conducted at different universities, pharmaceutical companies and government research departments. The report announced the existence of different forms of penicillin compounds which all shared the same structural component called β-lactam. The penicillins were designated by Roman numerals in UK (penicillin I, II, III and IV) in order of their discoveries, and known by letters (F, G, X, and K) referring to their origins or sources in the US, as below:
=== Names === Chloramphenicol is available as a generic worldwide under many brandnames and also under various generic names in eastern Europe and Russia, including chlornitromycin, levomycetin, and chloromycetin; the racemate is known as synthomycetin.
=== 2018–present: The feud reignites === The peace between the two rappers found itself to be short-lived as 50 Cent would reignite the feud in 2015 when Ja Rule gave a feedback to a social follower via Twitter over a similar feud between Meek Mill and Drake. Enraged, 50 Cent later responded with photos and comments via Instagram, only siding with Drake. The feud would fully resurface two years later when 50 Cent mocked Ja Rule's involvement in that year's ill-fated Fyre Festival in which numerous concertgoers were scammed in a poorly conceived event based on Ja Rule's business relationship with fraudster Billy McFarland. Jackson would further continue reigniting tensions on January 18, 2018; when he would once again attack Ja Rule on Big Boy's Neighborhood during an interview. Ja Rule immediately responded to 50 Cent's comments on twitter the very next day. Further adding to the hostility; Jackson would prank Ja Rule in October 2018 by purchasing 200 discounted front-row tickets for an upcoming show of his in Arlington, Texas for a total of US$3,000 via Groupon. Jackson later confirmed on social media that he bought the tickets with the express intention of forcing Ja Rule to perform in front of rows of empty seats. Tensions would briefly reignite between Eminem and Ja Rule as he would attack him on the track "The Ringer" from his 2018 album Kamikaze. During Eminem's followup response to Machine Gun Kelly's diss track "Rap Devil", he included several lines claiming to have taken part in ending the careers of both Ja Rule and Benzino on Killshot.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.